United States pharmaceutical companies have a total of 40 new antiretrovirals, three possible gene therapy treatments, and several therapeutic vaccine candidates under development for treatment of HIV, according to a new report from the Pharmaceutical Research and Manufacturers of America.

The Pharmaceutical Research and Manufacturers of America (PhRMA), a pharmaceutical company lobbying group, releases a report each year on HIV treatments under development at U.S. pharmaceutical companies. The report this year includes new antiretrovirals, gene therapies, and vaccine candidates, in addition to treatments for HIV-related conditions such as Kaposi’s sarcoma…

Las compañías farmacéuticas estadounidenses cuentan con un total de 40 nuevos antirretrovirales, tres posibles tratamientos de terapia génica y varias posibles vacunas terapéuticas en desarrollo para el tratamiento del VIH, según un nuevo informe generado por los “Investigadores y Productores Farmacéuticos de América”.

“Investigadores y Productores Farmacéuticos de América” (PhRMA, por sus siglas en inglés) es un grupo de presión sobre las empresas farmacéuticas que publica un informe anual acerca de los tratamientos del VIH en fase de desarrollo en las compañías farmacéuticas de los Estados Unidos. El informe de…

Although research is still inconclusive, some scientists have found that acetyl-L-carnitine (ALCAR), a natural antioxidant, has the potential to alleviate some of the effects of antiretroviral toxic neuropathy (ATN).

ATN is a painful neurological condition that can be caused by antiretroviral drugs that damage nerve cells, causing pain, tingling, and numbness. It is the most common form of a condition known as HIV-associated sensory neuropathy (HIV-SN).

HIV-SN is estimated to affect one third of individuals with HIV. It is a significant factor in nonadherence to, and discontinuation of, antiretroviral medications.…

A recent study finds Viread (tenofovir) and Emtriva (emtricitabine) are more effective nucleoside reverse transcriptase inhibitors (NRTIs) than Ziagen (abacavir) and Epivir (lamivudine) as an initial combination therapy for HIV. The results were published in the New England Journal of Medicine.

A typical initial antiretroviral therapy regimen for HIV-positive patients who have not received therapy consists of two types of drugs: two NRTIs together with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor. Until now, it was unclear which two NRTIs are the most effective and safe.…